Targeting the NLRP3 inflammasome in diabetic retinopathy: From pathogenesis to therapeutic strategies

Diabetic retinopathy (DR) is a common diabetic microvascular complication and the main cause of vision loss in working-aged people. The NLRP3 inflammasome is a cytosolic multimeric complex that plays a significant role in innate immunity. After sensing injury, the NLRP3 inflammasome induces inflammatory mediator secretion and triggers a form of inflammatory cell death known as pyroptosis. Studies over the past five years have shown increased expression of NLRP3 and related inflammatory mediators in vitreous samples from DR patients at different clinical stages. Many NLRP3-targeted inhibitors have shown great antiangiogenic and antiinflammatory effects in diabetes mellitus models, suggesting that the NLRP3 inflammasome is involved in the progression of DR. This review covers the molecular mechanisms of NLRP3 inflammasome activation. Furthermore, we discuss the implications of the NLRP3 inflammasome in DR, including the induction of pyroptosis and inflammation and the promotion of microangiopathy and retinal neurodegeneration. We also summarize the research progress on targeting the NLRP3 inflammasome in DR therapeutics with the expectation of providing new insights into DR progression and treatment.

Automated summary

Diabetic retinopathy (DR) is a common complication of diabetes and a major cause of vision loss. The NLRP3 inflammasome, an intracellular complex involved in innate immunity, plays a significant role in DR progression. Studies have shown increased expression of NLRP3 and related inflammatory mediators in vitreous samples from DR patients, and targeting the NLRP3 inflammasome has shown potential in DR therapeutics.